When it comes to building trust, attracting investors, negotiating deals, and making critical business decisions, understanding and articulating value is non-negotiable. For life sciences companies, valuations go beyond just numbers - they encapsulate the potential of a company’s innovation, the strength of its pipeline, and the commercial promise of its products. RhoneBio offers expert valuation services that empower your company with robust, credible, and independent insights, designed to inform strategy and instill confidence in stakeholders.
Why Valuations Matter in Life Sciences
Valuations are more than financial metrics - they are the backbone of every major milestone in the life sciences journey. From raising capital to partnering with pharma companies or preparing for an IPO, having a precise and well-documented valuation is critical.
• Investor Confidence: Investors want to see the economic viability and growth potential of your business before
committing capital. A detailed and independent valuation provides transparency and credibility.
• Pharma Partnerships: When licensing or co-developing products, pharma companies assess the value of your pipeline
and its alignment with their strategic goals. A robust valuation ensures your assets are accurately positioned.
• Strategic Insights: A valuation is not just an external tool-it also offers your management team key insights to
guide internal decision-making, portfolio prioritization, and resource allocation.
• Regulatory and Compliance Needs: Valuation reports are often required during funding rounds, mergers, or
acquisitions to comply with regulatory standards or legal obligations.
RhoneBio’s Expertise in Valuations
RhoneBio specialises in delivering tailored valuation reports that meet the unique needs of life sciences companies.
Whether you are preparing for a funding round, negotiating a licensing deal, or planning an exit, our deep industry
knowledge and strategic approach ensure that you are positioned for success.
Our valuation services include:
1. Product Valuations
• Assessing the commercial potential of pipeline or marketed products using methodologies like Net Present Value (NPV) or Risk-Adjusted Net Present Value (rNPV).
2. Company Valuations
• Evaluating your company’s market position, financial health, intellectual property portfolio, pipeline, and more to arrive at a comprehensive valuation.
3. Transaction Support
• Independent valuations to support deal-making processes such as licensing agreements, acquisitions, or co-development partnerships.
4. Scenario Modeling
• Conducting sensitivity analyses to explore various market or clinical scenarios and their impact on value.
The Valuation Methodologies We Use
We employ internationally recognized methodologies to deliver accurate and defensible valuations tailored to your specific context. Some of the most common methods include:
Net Present Value (NPV): A method based on the future cash flows of a product, discounted to their present value using an appropriate discount rate. This is particularly relevant for established revenue-generating products.
Risk-Adjusted Net Present Value (rNPV): This approach adjusts NPV calculations for the probability of success at various stages of a product’s development. It’s ideal for early-stage assets with inherent clinical and regulatory risks.
Comparable Company Analysis (CCA): Benchmarking your company or assets against similar companies or transactions to derive a fair market value.
Precedent Transaction Analysis (PTA): Assessing recent deals in the sector to determine how comparable assets or companies have been valued.
Discounted Cash Flow (DCF): Projecting the company’s cash flows over a certain period and discounting them to calculate present value.
Multiples Analysis: Using revenue or earnings multiples from comparable companies to estimate value, often used in later-stage companies or during M&A discussions.
Why Independent Valuations Are Essential
In today’s competitive and risk-averse funding environment, having an independent valuation is more important than ever. Life sciences companies can rely on RhoneBio for their valuation need because we offer:
• Credibility: Our independent valuations carry weight with investors, partners, and stakeholders, showing that your assessments are unbiased and professionally conducted.
• Negotiation Power: A strong valuation strengthens your position in deal-making, ensuring you secure terms that reflect the true value of your assets.
• Strategic Clarity: Our comprehensive reports don’t just provide numbers—they offer actionable insights that align your team on priorities and opportunities.
• Investor Attraction: Detailed valuation reports demonstrate your company’s preparedness, transparency, and potential, making it easier to win over investors.
• Focus on Life Sciences: Unlike generic valuation firms, we specialize in life sciences, offering unparalleled expertise in evaluating pharmaceuticals, biotech assets, medical devices, and diagnostics.
RhoneBio’s Approach: Tailored, Transparent, and Trusted
We understand that no two companies or products are the same. Our valuation process begins with a deep dive into your business, pipeline, and market environment. We have a professional approach:
Comprehensive Data Gathering: We gather all relevant data on your pipeline, market, and competitive landscape.
Rigorous Analysis: Using a combination of methodologies, we create detailed models tailored to your specific needs and goals.
Collaborative Process: We work closely with your team to ensure the valuation reflects your unique strengths and strategic vision.
Clear Reporting: Our reports are designed to be both detailed and accessible, with clear narratives, charts, and insights to communicate your value effectively.
